

CITATION REPORT

List of articles citing

Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology

DOI: 10.1002/ejhf.1461

European Journal of Heart Failure, 2019, 21, 553-576.

Source: <https://exaly.com/paper-pdf/73340625/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
167	Targeting CD20+ B-lymphocytes in inflammatory dilated cardiomyopathy with rituximab improves clinical course: a case series. <i>European Heart Journal - Case Reports</i> , 2019 , 3,	0.9	15
166	Renin Activity in Heart Failure with Reduced Systolic Function-New Insights. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	10
165	The eyes are the mirror of the heart: role of retinal microvascular abnormalities in predicting long-term risk of heart failure. <i>European Journal of Heart Failure</i> , 2019 , 21, 1216-1218	12.3	
164	Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	3
163	How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). 2019 , 40, 3297-3317		379
162	May 2019 at a glance: epidemiology, drug effects on biomarkers, adverse events with LVAD. <i>European Journal of Heart Failure</i> , 2019 , 21, 541-542	12.3	
161	Use of Cardiac Biomarkers for Monitoring Improvement of Left Ventricular Function by Immunoabsorption Treatment in Dilated Cardiomyopathy. 2019 , 9,		4
160	Figures of the Heart Failure Association (HFA): Prof. Dr. Jelena Blutkienė HFA Board Member (2016-2020) and co-coordinator of the Imaging Study Group of the HFA Diagnosis Committee. <i>European Journal of Heart Failure</i> , 2019 , 21, 1487-1489	12.3	
159	Heart failure in dilated non-ischaemic cardiomyopathy. 2019 , 21, M40-M43		8
158	Current understanding of fibrosis in genetic cardiomyopathies. 2020 , 30, 353-361		21
157	Biomarkers in Heart Failure With Preserved Ejection Fraction: An Update on Progress and Future Challenges. 2020 , 29, 62-68		7
156	Hypertrophic cardiomyopathy: the future of treatment. <i>European Journal of Heart Failure</i> , 2020 , 22, 228-240		25
155	Dilated cardiomyopathy: so many cardiomyopathies!. 2020 , 41, 3784-3786		13
154	July 2020 at a glance: focus on imaging and cardiomyopathies. <i>European Journal of Heart Failure</i> , 2020 , 22, 1057-1059	12.3	
153	F-flutemetamol positron emission tomography in cardiac amyloidosis. 2020 , 1		3
152	Heart failure from ATTRwt amyloid cardiomyopathy is associated with poor prognosis. <i>ESC Heart Failure</i> , 2020 , 7, 3919	3.7	7
151	Modulation of the acute defence reaction by eplerenone prevents cardiac disease progression in viral myocarditis. <i>ESC Heart Failure</i> , 2020 , 7, 2838-2852	3.7	5

150 Hypertrophic cardiomyopathy. **2020**, 347-361

149 Risk stratification in cardiomyopathy. **2020**, 27, 52-58

4

148 Heart failure in the last year: progress and perspective. *ESC Heart Failure*, **2020**, 7, 3505

3.7 24

147 Prevalence, causes and predictors of cardiovascular hospitalization in patients with hypertrophic cardiomyopathy. **2020**, 318, 94-100

2

146 Die Zukunft der Nuklearkardiologie. **2020**, 43, 14-19

145 Giant cell myocarditis in an older patient - reassessing the threshold for endomyocardial biopsy. *ESC Heart Failure*, **2020**, 7, 3165-3168

3.7 2

144 Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet, The*, **2020**, 396, 759-769

40 149

143 Small Molecules acting on Myofilaments as Treatments for Heart and Skeletal Muscle Diseases. *International Journal of Molecular Sciences*, **2020**, 21,

6.3 13

142 A new perspective of an old tool: an everlasting benefit of the electrocardiogram in dilated cardiomyopathy. *European Journal of Heart Failure*, **2020**, 22, 1108-1110

12.3

141 Cardiovascular magnetic resonance native T and T quantitative values for cardiomyopathies and heart transplantations: a systematic review and meta-analysis. **2020**, 22, 34

7

140 Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers. **2020**, 2020, 1215802

21

139 March 2020 at a glance: heart failure with preserved ejection fraction, left atrial myopathy, atrial fibrillation and cardiac amyloidosis. *European Journal of Heart Failure*, **2020**, 22, 389-390

12.3 1

138 How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). *European Journal of Heart Failure*, **2020**, 22, 391-412

12.3 84

137 The sex gap in hypertrophic cardiomyopathy. **2020**, 73, 1018-1025

1

136 Practice makes perfect: improved long-term survival in non-ischaeic dilated cardiomyopathy with contemporary treatment. *European Journal of Heart Failure*, **2020**, 22, 1122-1124

12.3

135 Cardiomyopathies-past, present, future. **2020**, 45, 209-211

134 The neglected issue of cardiac amyloidosis in trials on heart failure with preserved ejection fraction in the elderly. *European Journal of Heart Failure*, **2020**, 22, 1740-1741

12.3 5

133 The electrocardiogram in the diagnosis and management of patients with dilated cardiomyopathy. *European Journal of Heart Failure*, **2020**, 22, 1097-1107

12.3 18

132	Precision medicine in distinct heart failure phenotypes: Focus on clinical epigenetics. 2020 , 224, 113-128		37
131	Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	9
130	Human-induced pluripotent stem cells for modelling metabolic perturbations and impaired bioenergetics underlying cardiomyopathies. 2021 , 117, 694-711		4
129	Prospective follow-up in various subtypes of cardiomyopathies: insights from the ESC EORP Cardiomyopathy Registry. 2021 , 7, 134-142		0
128	Hypertrophic Cardiomyopathy in Pregnancy. 2021 , 39, 143-150		3
127	Cardiovascular Magnetic Resonance in Heritable Cardiomyopathies. 2021 , 17, 25-39		
126	Global longitudinal diastolic strain rate as a novel marker for predicting adverse outcomes in hypertrophic cardiomyopathy by cardiac magnetic resonance tissue tracking. 2021 , 76, 78.e19-78.e25		3
125	Effects of Angiotensin II Receptor Blockers on Ventricular Hypertrophy in Hypertrophic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials. 2021 , 1		0
124	Mitochondrial Dysfunction and Heart Disease: Critical Appraisal of an Overlooked Association. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	11
123	The Importance of Multimodality Imaging in the Diagnosis and Management of Patients with Infiltrative Cardiomyopathies: An Update. 2021 , 11,		2
122	Predicting the clinical course in hypertrophic cardiomyopathy using thallium-201 myocardial scintigraphy. <i>ESC Heart Failure</i> , 2021 , 8, 1378-1387	3.7	2
121	February 2021 at a glance: focus on amyloidosis, myocarditis and cardiomyopathy. <i>European Journal of Heart Failure</i> , 2021 , 23, 201-202	12.3	
120	Gemcitabine-induced dilated-cardiomyopathy in patient with platinum-refractory ovarian-cancer: A case report and literature review. 2021 , 27, 1542-1547		1
119	Cardiometabolism as an Interlocking Puzzle between the Healthy and Diseased Heart: New Frontiers in Therapeutic Applications. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	5
118	Cardiogenic Shock in Obstructive Hypertrophic Cardiomyopathy Plus Apical Ballooning: Management With VA-ECMO and Myectomy. 2021 , 3, 433-437		1
117	Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. <i>European Journal of Heart Failure</i> , 2021 , 23, 527-540	12.3	10
116	Genetic Cardiomyopathies: The Lesson Learned from hiPSCs. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
115	Cardiovascular Magnetic Resonance Imaging and Heart Failure. 2021 , 23, 35		2

114	Cardiomyopathies and Genetic Testing in Heart Failure: Role in Defining Phenotype-Targeted Approaches and Management. 2021 , 37, 547-559		6
113	Role of Cardiac Magnetic Resonance Imaging in Heart Failure. 2021 , 17, 207-221		1
112	Cardiac Resynchronization Therapy in Patients with Heart Failure: What is New?. 2021 , 17, 289-301		1
111	Biomarkers in Heart Failure: Clinical Insights. 2021 , 17, 223-243		5
110	Immunoabsorption for heart failure is associated with normalization of iron metabolism. 2021 , 26, 395-400		0
109	Genome-wide association study of cardiac troponin I in the general population. 2021 , 30, 2027-2039		5
108	Consensus on basic conduct during the hospital admission of patients with acute heart failure. 2021 , 221, 283-296		
107	Consensus on basic conduct during the hospital admission of patients with acute heart failure. 2020 , ,		1
106	Adaptive anti-myocardial immune response following hospitalization for acute heart failure. <i>ESC Heart Failure</i> , 2021 , 8, 3348-3353	3-7	2
105	Cardiovascular magnetic resonance detects microvascular dysfunction in a mouse model of hypertrophic cardiomyopathy. 2021 , 23, 63		0
104	Current patterns of beta-blocker prescription in cardiac amyloidosis: an Italian nationwide survey. <i>ESC Heart Failure</i> , 2021 , 8, 3369-3374	3-7	3
103	2020 Clinical practice guidelines for Hypertrophic cardiomyopathy. <i>Russian Journal of Cardiology</i> , 2021 , 26, 4541	1-3	6
102	June 2021 at a glance: focus on epidemiology, biomarkers and medical treatment. <i>European Journal of Heart Failure</i> , 2021 , 23, 847-849	12-3	
101	Cardiovascular disease burden: Italian and global perspectives. 2021 , 69, 231-240		5
100	Dilated cardiomyopathy: a new insight into the rare but common cause of heart failure. 2021 , 1		2
99	Immunoabsorption treatment for dilated cardiomyopathy: A PRISMA-compliant systematic review and meta-analysis. 2021 , 100, e26475		2
98	CMR-Based Risk Stratification of Sudden Cardiac Death and Use of Implantable Cardioverter-Defibrillator in Non-Ischemic Cardiomyopathy. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6-3	2
97	August 2021 at a glance: focus on cardiomyopathies, medical treatment and devices. <i>European Journal of Heart Failure</i> , 2021 , 23, 1247-1249	12-3	

96	Cell therapy for nonischemic dilated cardiomyopathy: A systematic review and meta-analysis of randomized controlled trials. 2021 , 10, 1394-1405	2
95	Contemporary etiology and prognosis of dilated non-ischemic cardiomyopathy. 2021 ,	1
94	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. 2021 , 42, 3599-3726	875
93	Contemporary contribution of cardiac surgery for the treatment of cardiomyopathies and pericardial diseases. 2021 ,	
92	Insights Into Genetics and Pathophysiology of Arrhythmogenic Cardiomyopathy. 2021 , 18, 378-390	4
91	Cardiomyopathy and Pregnancy: Considerations for Women With Severe Reduced Left Ventricular Dysfunction. 2021 ,	0
90	Protein Aggregation Is an Early Manifestation of Phospholamban p.(Arg14del)-Related Cardiomyopathy: Development of PLN-R14del-Related Cardiomyopathy. 2021 , 14, e008532	2
89	Echocardiographic evaluation of hypertrophic cardiomyopathy: A review of up-to-date knowledge and practical tips. 2021 , 38, 1795-1808	0
88	Advanced Heart Failure in Special Population: Cardiomyopathies and Myocarditis. 2021 , 17, 661-672	0
87	3D models of dilated cardiomyopathy: Shaping the chemical, physical and topographical properties of biomaterials to mimic the cardiac extracellular matrix. 2022 , 7, 275-291	1
86	Dual-modality Volume Measurement integrated on a Ventricular Assist Device. 2021 , PP,	
85	Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy. 2020 , 75, 2649-2660	58
84	Quantification of myocardial Tc-labeled bisphosphonate uptake with cadmium zinc telluride camera in patients with transthyretin-related cardiac amyloidosis. 2019 , 9, 117	8
83	Antithrombotic Treatment in Cardiomyopathies. 2020 , 26, 2762-2768	0
82	The Molecular Mechanisms Associated with Aerobic Exercise-Induced Cardiac Regeneration. 2020 , 11,	7
81	Women and Diabetes: Preventing Heart Disease in a New Era of Therapies. 2021 , 16, e40	1
80	The Role of Ferroptosis in Cardiovascular Disease and Its Therapeutic Significance. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 733229	5-4 4
79	Electrical Ventricular Remodeling in Dilated Cardiomyopathy. 2021 , 10,	0

78	Protocolo diagnóstico de las miocardiopatías. 2021 , 13, 2486-2489		
77	Miocardiopatía dilatada. 2021 , 13, 2447-2458		
76	The clinical case of familial restrictive cardiomyopathy. 2019 , 64, 215-219		
75	Old and New Drugs for Treatment of Advanced Heart Failure. 2020 , 26, 1571-1583		1
74	What can hide behind an "idiopathic" dilated cardiomyopathy?. 2020 , 7, 28-33		
73	Emerging therapy in light-chain and acquired transthyretin-related amyloidosis: an Italian single-centre experience in heart transplantation. <i>Journal of Cardiovascular Medicine</i> , 2021 , 22, 261-267	1.9	2
72	Using human genetics to understand the causes and consequences of circulating cardiac troponin I in the general population.		
71	Impact of cibenzoline treatment on left ventricular remodelling and prognosis in hypertrophic obstructive cardiomyopathy. <i>ESC Heart Failure</i> , 2021 , 8, 4832	3.7	2
70	Brecha de sexo en la miocardiopatía hipertrófica. <i>Revista Española De Cardiología</i> , 2020 , 73, 1018-1025	1.5	0
69	Analysis of Selected Cardiovascular Biomarkers in Takotsubo Cardiomyopathy and the Most Frequent Cardiomyopathies. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 700169	5.4	1
68	Progressive myocardial injury in myotonic dystrophy type II and facioscapulohumeral muscular dystrophy 1: a cardiovascular magnetic resonance follow-up study. 2021 , 23, 130		0
67	Management of nonischemic-dilated cardiomyopathies in clinical practice: a position paper of the working group on myocardial and pericardial diseases of Italian Society of Cardiology. <i>Journal of Cardiovascular Medicine</i> , 2020 , 21, 927-943	1.9	1
66	Contribution of electrocardiography to the diagnosis of cardiomyopathies and athletic heart syndrome. <i>Russian Journal of Cardiology</i> , 25, 4023	1.3	1
65	Association Between Heart Failure With Preserved Left Ventricular Ejection Fraction and Impaired Left Atrial Phasic Function in Hypertrophic Cardiomyopathy: Evaluation by Cardiac MRI Feature Tracking. <i>Journal of Magnetic Resonance Imaging</i> , 2021 ,	5.6	1
64	The Ratio of NT-proBNP to CysC Predicts Heart Failure in Patients With Chronic Kidney Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 731864	5.4	2
63	Beta-Blocker Exposure and Survival in Patients With Transthyretin Amyloid Cardiomyopathy. <i>Mayo Clinic Proceedings</i> , 2021 ,	6.4	2
62	Therapeutic inhibition of RBM20 improves diastolic function in a murine heart failure model and human engineered heart tissue. <i>Science Translational Medicine</i> , 2021 , 13, eabe8952	17.5	2
61	(Expert consensus on the practical aspects of collaboration between cardiologists and diabetologists in the management of patients with chronic heart failure with reduced ejection fraction). <i>Cor Et Vasa</i> , 2021 , 63, 630-636	0.3	

60	Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: From molecular mechanisms to therapeutic targets.. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	2
59	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC.. <i>European Journal of Heart Failure</i> , 2022 , 24, 4-131	12.3	50
58	A novel Troponin I mutation associated with severe restrictive cardiomyopathy-a case report of a 27-year-old woman with fatigue.. <i>European Heart Journal - Case Reports</i> , 2022 , 6, ytac053	0.9	0
57	Mitochondrial-Targeted Therapy for Doxorubicin-Induced Cardiotoxicity.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	6
56	Identification of Immune Markers in Dilated Cardiomyopathies with Heart Failure by Integrated Weighted Gene Coexpression Network Analysis.. <i>Genes</i> , 2022 , 13,	4.2	0
55	Genotype-Phenotype Correlation in Familial Mutation Dilated Cardiomyopathy.. <i>Genes</i> , 2022 , 13,	4.2	0
54	Advances in Multimodality Cardiovascular Imaging in the Diagnosis of Heart Failure With Preserved Ejection Fraction.. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 758975	5.4	0
53	Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.. <i>Lancet, The</i> , 2022 , 399, 1049-1058	4.0	6
52	Metabolomics Fingerprint Predicts Risk of Death in Dilated Cardiomyopathy and Heart Failure.. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 851905	5.4	0
51	Genetic Insights into Primary Restrictive Cardiomyopathy.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	0
50	A year in heart failure: an update of recent findings.. <i>ESC Heart Failure</i> , 2021 , 8, 4370-4393	3.7	4
49	Optimal Heart Rate and Prognosis in Patients with Cardiac Amyloidosis.. <i>Journal of Cardiovascular Development and Disease</i> , 2021 , 8,	4.2	0
48	Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. <i>Revista Española De Cardiología</i> , 2022 ,	1.5	1
47	Adipose tissue distribution is associated with cardio-metabolic alterations in adult patients with juvenile-onset dermatomyositis.. <i>Rheumatology</i> , 2022 ,	3.9	0
46	Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics.. <i>Journal of Molecular Cell Biology</i> , 2022 ,	6.3	1
45	Impaired Myocardial Mitochondrial Function in an Experimental Model of Anaphylactic Shock. <i>Biology</i> , 2022 , 11, 730	4.9	1
44	Left ventricular dysfunction with preserved ejection fraction: the most common left ventricular disorder in chronic kidney disease patients. <i>CKJ: Clinical Kidney Journal</i> ,	4.5	1
43	Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument. <i>Pharmacoeconomics - Open</i> ,	2.1	0

42	Specific microRNAs and heart failure: time for the next step toward application?. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia,</i>	1.7	1
41	Clinical Features of Heart Failure in Patients With Hypertrophic Cardiomyopathy in a Regional Japanese Cohort [Results From the Kochi RYOMA Study] <i>Circulation Journal, 2022,</i>	2.9	0
40	Simple Way of Identifying High-Risk Group of Heart Failure in Hypertrophic Cardiomyopathy in the Japanese Population. <i>Circulation Journal, 2022,</i>	2.9	
39	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-Ninth Adult Heart Transplantation Report [2022; Focus on Transplant for Restrictive Heart Disease. <i>Journal of Heart and Lung Transplantation, 2022,</i>	5.8	1
38	The activin receptor ligand trap ActRIIB : ALK4-Fc ameliorates cardiomyopathy induced by neuromuscular disease and diabetes.		
37	Impact of Tafamidis on Survival in a Real World Community-Based Cohort. 2022, 101358		0
36	2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.		37
35	Hypertrophe Kardiomyopathien und die kardiale ATTR-Amyloidose [eine aktuelle Übersicht f�ur den klinischen Alltag. 2022, 147, 1127-1134		0
34	Heart Failure and Cardiomyopathies: CT and MR from Basics to Advanced Imaging. 2022, 12, 2298		0
33	Familial risk of dilated and hypertrophic cardiomyopathy: a national family study in Sweden.		0
32	Gaseous signal molecule SO2 regulates autophagy through PI3K/AKT pathway inhibits cardiomyocyte apoptosis and improves myocardial fibrosis in rats with type II diabetes. 2022, 26, 541-556		0
31	(Illness perception and its connection with chosen characteristics in heart failure patients). 2022, 64, 510-516		0
30	Hypertrophic Cardiomyopathies at the Sylvanus Olympio Teaching Hospital of Lome: Epidemiological, Diagnostic, Therapeutic and Evolutive Aspects. 2022, 12, 481-491		0
29	Design and Development of a Heterogeneous Active Assisted Living Solution for Monitoring and Following Up with Chronic Heart Failure Patients in Spain. 2022, 22, 8961		1
28	Genome Editing and Heart Failure. 2023, 75-85		0
27	Genotyping Indian patients with primary cardiomyopathies-analysis of database. 2022,		0
26	Integrated analysis of WGCNA and machine learning identified diagnostic biomarkers in dilated cardiomyopathy with heart failure. 10,		0
25	Immunoabsorption therapy in refractory heart failure patients with dilated cardiomyopathy: a potential therapeutic option.		0

- 24 Clinical scenarios of HCM-related mortality: Relevance of age and stage of disease at presentation. **2023**, 0
- 23 Gliflozins: From Antidiabetic Drugs to Cornerstone in Heart Failure Therapy—A Boost to Their Utilization and Multidisciplinary Approach in the Management of Heart Failure. **2023**, 12, 379 1
- 22 Volume-Weighted Unipolar Voltage Predicts Heart Failure Mortality in Patients With Dilated Cardiomyopathy and Ventricular Arrhythmias. **2023**, 0
- 21 Receptor autoantibodies: Associations with cardiac markers, histology, and function in human non-ischaemic heart failure. 0
- 20 Myokarditis. **2023**, 1-14 0
- 19 Is Hypovitaminosis D a Risk Factor for Heart Failure?. **2023**, 13, 372 0
- 18 Dysregulation of Iron Metabolism-Linked Genes at Myocardial Tissue and Cell Levels in Dilated Cardiomyopathy. **2023**, 24, 2887 0
- 17 Prevalence and Impact of Arrhythmia on Outcomes in Restrictive Cardiomyopathy—A Report from the Beijing Municipal Health Commission Information Center (BMHCIC) Database. **2023**, 12, 1236 0
- 16 Cell death regulation in myocardial toxicity induced by antineoplastic drugs. 11, 0
- 15 Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis. 10, 0
- 14 Simple screening model based on electrocardiogram for patients with dilated cardiomyopathy. **2023**, 102, e32910 0
- 13 Hypertrophic, Dilated, and Arrhythmogenic Cardiomyopathy: Where Are We?. **2023**, 11, 524 0
- 12 Workup of difficult-to-treat asthma: implications from treatable traits. **2023**, 6, 0
- 11 Dilated cardiomyopathy with anti-mitochondrial M2 antibody: A case series. **2023**, 0
- 10 Holistic approach to drug therapy in a patient with heart failure. heartjnl-2022-321764 0
- 9 Relationships of Whole-Heart Myocardial Mechanics and Cardiac Morphometrics by Transthoracic Echocardiography with Main Prognostic Factors of Heart Failure in Non-Ischemic Dilated Cardiomyopathy. **2023**, 12, 2272 0
- 8 Prognostic value of summed motion score assessed by gated SPECT myocardial perfusion imaging in patients with dilated cardiomyopathy. 10, 0
- 7 Development and validation of nomogram for unplanned ICU admission in patients with dilated cardiomyopathy. 10, 0

- 6 News in diagnostics and treatment of cardiomyopathies. **2023**, 69, 89-104 ○
- 5 Guidelines on the Use of Therapeutic Apheresis in Clinical Practice [Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. **2023**, 38, 77-278 ○
- 4 Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Definition and Diagnosis. 53, ○
- 3 Differences in phenotypes, symptoms, and survival in patients with cardiomyopathy: prospective observational study from the Sahlgrenska CardioMyoPathy Centre. 10, ○
- 2 Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Definition and Diagnosis. 5, ○
- 1 Diagnostic and prognostic role of late gadolinium enhancement in cardiomyopathies. **2023**, 25, C130-C136 ○